{
  "docId": "019de074-d961-7389-a20b-cd17e719b042",
  "docSlug": "eb72a4aa6f7d8bed68bc577a406605bf",
  "documentTitle": "BioAtla | Investor Presentation Deck | 44 slides",
  "authorId": "bioatla",
  "authorName": "BioAtla",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 24,
  "pageCount": 44,
  "prevPage": 23,
  "nextPage": 25,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 9,
  "notes": "Includes abbreviations for LMS, UPS, and NSCLC at the bottom.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-d961-7389-a20b-cd17e719b042/24",
  "deckHref": "/decks/019de074-d961-7389-a20b-cd17e719b042",
  "deckJsonHref": "/decks/019de074-d961-7389-a20b-cd17e719b042.json",
  "deckAnchorHref": "/decks/019de074-d961-7389-a20b-cd17e719b042#slide-24",
  "components": [
    {
      "bbox": {
        "h": 0.04,
        "w": 0.5,
        "x": 0.12,
        "y": 0.94
      },
      "kind": "paragraph",
      "text": "*Investigator-initiated trial. LMS, leiomyosarcoma; UPS, undifferentiated pleomorphic sarcoma; NSCLC, non small cell lung cancer.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e5d082e9-4773-490e-bc45-061ab4008889",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.86,
        "x": 0.07,
        "y": 0.205
      },
      "kind": "table",
      "text": "Indication, Dose, Patient #. Soft tissue and bone sarcoma, Q2W monotherapy and combo w/ nivolumab, ~15 per cohort. LMS, 3Q4W monotherapy, N ~ 15. UPS, 2Q3W monotherapy / 3Q4W monotherapy, N ~ 20. NSCLC, Q2W monotherapy / Q2W in combo w/ nivolumab / 2Q3W monotherapy / 3Q4W monotherapy, N ~ 20. Ovarian*, Q2W in combo w/ durvalumab, N ~ 20.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b5a30e3-d6eb-47ff-a65c-90b73b27c965",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "Summary of Dosing Regimens for Phase 2 Clinical Studies with CAB-AXL-ADC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8bf4943b-4a61-4fc0-a941-c4b3eea73e6a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "436133dd-f3c5-4936-8e91-daf5660046f2",
      "evidence": "Table showing dosing schedules for Q2W, 2Q3W, and 3Q4W regimens",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}